El interés en corto de Roadzen da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Roadzen. Los datos de interés en corto se actualizan cada dos semanas.

Roadzen (NASDAQ:RDZN) Bolsa, Informe de interés en corto

Roadzen

Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.

Roadzen Inc

Macro Economic Events

News

Econ #s

Economics

USA Retail Inventories Ex Auto For January 0.5% Vs 0.4% Est.; -0.1% Prior

4 analysts have expressed a variety of opinions on FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.25, with a high estimate of $22.00 and a low estimate of $19.00. This current average has increased by 2.41% from the previous average price target of $20.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220034_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive FS KKR Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to FS KKR Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FS KKR Capital compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of FS KKR Capital's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FS KKR Capital analyst ratings.</a>
<h2>About FS KKR Capital</h2>
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
<h3>Key Indicators: FS KKR Capital's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining FS KKR Capital's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 42.64% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: FS KKR Capital's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 79.89% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): FS KKR Capital's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.21%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: FS KKR Capital's debt-to-equity ratio is below the industry average at 1.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into FS KKR Capital Stock: Analyst Perspectives (4 Ratings)

Even the <a href="https://www.benzinga.com/news/24/12/42638666/rockefeller-rich-elon-musks-wealth-hits-rockefeller-rich-levels-equivalent-to-a-1-6-share-of-the-u-s-gdp">world's richest man</a> isn't immune to financial headaches, and apparently, neither is his family. Elon Musk, whose net worth still hovers around $330 billion despite record losses recently, isn't the only one navigating the highs and lows of wealth. His sister, Tosca Musk, says having the last name "Musk" comes with a price—literally.
Tosca, a filmmaker and the founder of Passionflix, revealed that when scouting locations for a production, she encountered a steep markup simply because of her famous last name.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
"The location was going to cost $5,000 a day," Tosca told the <a href="https://www.dailymail.co.uk/femail/article-12208147/Tosca-Musk-reveals-assumes-Elon-pays-picked-sperm-donor.html">Daily Mail in 2023</a>. "But when they heard my name and assumed we were rich, they decided to charge us $25,000."
That's a 400% increase—simply for being related to Elon Musk.
<h2 class="wp-block-heading">The Double-Edged Sword of the Musk Name</h2>
Tosca admitted that the Musk name is both a "blessing and a curse." While it undoubtedly opens doors, it also comes with assumptions—many of which aren't true.
"Everyone assumes my eldest brother pays for everything, but he does not," she said, explaining that while she and Elon share a strong sibling bond, he's not bankrolling her ventures.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
"It's a double-edged sword for me to say whether my brother has helped in any way. If I say no, then people will say he does not support me at all, and if I say yes, they'll think he paid for everything."
She founded Passionflix in 2017 to adapt romance novels into films, after struggling to get traditional networks or studios interested in the genre. Despite being part of one of the world's most well-known families, funding the company wasn't easy.
<h2 class="wp-block-heading">A Family That Wasn't Born Rich</h2>
The Musk siblings—Elon, Tosca, and Kimbal—didn't grow up in the kind of wealth many assume. Their mother, Maye Musk, worked as a model while raising them, often bringing them to her jobs because <a href="https://www.benzinga.com/personal-finance/25/01/42771425/elon-musks-mom-says-struggling-parents-can-skip-the-movies-or-dining-out-just-spend-time-with-the-most-wonderful-gifts-you-can-ever-have">she couldn't afford childcare</a>.
"As children, we were given a lot of freedom, but with it came responsibility," Tosca recalled. "You had to take care of yourself, learn how to cook and clean, and be supportive of the people who were doing everything they could to support you in life."
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
That mindset carried over into her own parenting. When faced with public scrutiny, she reassured her children by reminding them that public perception doesn't define them.
"I told my kids, ‘Do you know us and do you think that's who we are? If you know what the truth is about our family, don't believe what others say.'"
<h2 class="wp-block-heading">Ambitions Beyond the Musk Name</h2>
Despite the challenges of being a Musk, Tosca has no desire to change her last name.
"It's mostly a blessing, and I would never be tempted to change it," she said. "Even if it means getting upcharged."
As for her future goals? "I'd like our films to win some Emmys, an Oscar, maybe a BAFTA—all the awards—so that people will pay attention to romance."
With a name like Musk, <a href="https://www.benzinga.com/startups/25/01/43101102/elon-musk-the-richest-man-in-the-world-is-estimated-to-earn-over-23-million-every-single-hour-of-the-day-heres-how-hes-spending-it">people are definitely paying attention</a>.
Read Next:
<ul>
<li>Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

Elon Musk's Little Sister Says Her Last Name Is a 'Blessing and a Curse'—Prices Soar When People Realize Her Brother Is the World's Richest Man

Analysts' ratings for Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $13.67, a high estimate of $17.00, and a low estimate of $10.00. Witnessing a positive shift, the current average has risen by 3.17% from the previous average price target of $13.25.
<img src="https://www.benzinga.com/files/images/story/2025/1742220026_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rivian Automotive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Murphy</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Rivian Automotive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rivian Automotive compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Rivian Automotive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Rivian Automotive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RIVN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rivian Automotive analyst ratings.</a>
<h2>Discovering Rivian Automotive: A Closer Look</h2>
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues primarily from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
<h3>Understanding the Numbers: Rivian Automotive's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Rivian Automotive showcased positive performance, achieving a revenue growth rate of 31.86% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -42.91%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Rivian Automotive's ROE excels beyond industry benchmarks, reaching -11.95%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Rivian Automotive's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RIVN

What 12 Analyst Ratings Have To Say About Rivian Automotive

During the last three months, 14 analysts shared their evaluations of Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.43, a high estimate of $45.00, and a low estimate of $32.00. This current average has increased by 8.01% from the previous average price target of $37.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1742220017_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Range Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bertrand Hodee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Umang Choudhary</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bertrand Hodee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Range Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Range Resources compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Range Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Range Resources's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Range Resources analyst ratings.</a>
<h2>Delving into Range Resources's Background</h2>
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
<h3>A Deep Dive into Range Resources's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Range Resources showcased positive performance, achieving a revenue growth rate of 4.5% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Range Resources's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 14.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Range Resources's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.42%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Range Resources's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.29%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.46.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 14 Analysts Discuss Range Resources Stock

USA Business Inventories (MoM) For January 0.3% Vs 0.3% Est.; -0.2% Prior

MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) has outperformed the market over the past 5 years by 71.4% on an annualized basis producing an average annual return of 91.27%. Currently, MARA Holdings has a market capitalization of $4.49 billion. 
Buying $100 In MARA: If an investor had bought $100 of MARA stock 5 years ago, it would be worth $2,753.54 today based on a price of $13.22 for MARA at the time of writing.
<h3>MARA Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742220010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MARA

Here's How Much $100 Invested In MARA Holdings 5 Years Ago Would Be Worth Today

NAHB Housing Market Index For March 39 Vs 42 Est.; 42 Prior

Canadian Pacific Kansas City (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) (CPKC) today said that United Steelworkers (USW), representing approximately 600 clerical and intermodal employees in Canada, has ratified a new&nbsp;four-year collective agreement.

TSX:CP

Canadian Pacific Kansas City Says United Steelworkers, Representing ~600 Clerical And Intermodal Employees In Canada, Has Ratified A New 4-Year Collective Agreement

Citizens Capital Markets analyst Devin Ryan reiterates Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Market Outperform and maintains $94 price target.

Price Target

Reiteration

SCHW

Citizens Capital Markets Reiterates Market Outperform on Charles Schwab, Maintains $94 Price Target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

Regencell Bioscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 34.9%

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Guidance

SKYX

SKYX Platforms Sees Prelim. Q4 Revenue $23.7M Vs $24.3M Est.

Citizens Capital Markets analyst Aaron Hecht reiterates Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) with a Market Outperform and maintains $20 price target.

REFI

Citizens Capital Markets Reiterates Market Outperform on Chicago Atlantic Real, Maintains $20 Price Target

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)&nbsp;released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">hidradenitis suppurativa (HS)</a>.
Hidradenitis suppurativa (HS), also known as acne inversa, is&nbsp;a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead to abscesses and scarring.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44245346/eli-lilly-incyte-partnered-fda-approved-drug-shows-encouraging-efficacy-in-adolescent-patients-with-patchy-hair-loss" rel="noreferrer noopener">Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss</a>
STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg).
A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44352766/incyte-announces-positive-topline-results-from-two-phase-3-clinical-trials-of-povorcitinib-in-pati" rel="noreferrer noopener">draining tunnel count</a>.
The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:
<ul>
<li>STOP-HS1: 45 mg: 40.2% vs. 29.7% [P=0.024]; 75 mg: 40.6% vs 29.7% [P=0.022].</li>
<li>STOP-HS2: 45 mg: 42.3% vs. 28.6% [P=0.004]; 75 mg: 42.3% vs. 28.6% [P=0.003].</li>
</ul>
Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo:
<ul>
<li>STOP-HS1: 45 mg: 34.2% vs. 21.9% [P=0.096]; 75 mg: 37.8% vs. 21.9% [P=0.037].</li>
<li>STOP-HS2: 45 mg: 45.0% vs. 19.5% [P=0.001]; 75 mg: 40.0% vs. 19.5% [P=0.005].</li>
</ul>
In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares,&nbsp;&gt;3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30.
Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.
Last week, Incyte revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with prurigo nodularis, a chronic skin condition characterized by <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44229321/incyte-releases-mixed-data-from-late-stage-opzelura-studies-in-skin-disease-characterized-by-itchy-firm-lumps" rel="noreferrer noopener">very itchy firm lumps</a>.
Price Action: INCY stock is down 11.90% at $59.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44355022/science-applications-q4-earnings-crush-estimates-helped-by-new-contract-volume" target="_blank" rel="noreferrer noopener">Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

INCY

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

Citizens Capital Markets analyst Trevor Walsh reiterates Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Market Outperform and maintains $180 price target.

Citizens Capital Markets Reiterates Market Outperform on Cloudflare, Maintains $180 Price Target

Citizens Capital Markets analyst Aaron Hecht reiterates Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Market Perform to Market Perform.

IIPR

Citizens Capital Markets Reiterates Market Perform on Innovative Ind Propsto Market Perform

VCSA

Vacasa Accepts Casago's Revised Acquisition Proposal To Increase Price To $5.30/Share

Citizens Capital Markets analyst Brian McKenna reiterates FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) from Market Outperform to Market Outperform.

Citizens Capital Markets Reiterates Market Outperform on FTAI Infrastructureto Market Outperform

Contracts

Press Releases

Roadzen Expands its AI Based Claims Contract with One of the Top 10 P&C Insurers in India

Roadzen's drivebuddyAI Partners with Bosch to Advance AI-Driven Road Safety

Roadzen Partners with Simple Energy and a Leading Global Reinsurer to Provide AI-Driven Extended Warranty for Electric Two-Wheelers

Financing

Roadzen Inc. Announces Pricing of Offering

Roadzen Inc. Announces Closing of Public Offering

Roadzen Adds DeepSeek R1 to Mixtape, Delivering Advanced Reasoning and Data Sovereignty for Insurance and Mobility AI Agents

Roadzen Strengthens Balance Sheet, Eliminates $5.5 Million in Short-Term Liabilities By Paying $1.65 million in Cash

Earnings

Roadzen Reports Fiscal Third Quarter and First Nine-Months FY2025 Financial Results

Roadzen's MixtapeAI Wins 'Best AI in Deep Tech' at the Entrepreneur AI Awards 2025

Legal

Roadzen's DrivebuddyAI Awarded Patent for AI-Driven Driver Risk Assessment, Transforming Global Road Safety

RDZN

ACCESS Newswire

AudioEye

ReAlpha Tech

XIAO-I Corporation - American Depositary Shares

XIAO-I

Aware

BTCS

Cheetah Mobile Inc. American Depositary Shares, each representing fifty (50) Class A Ordinary Shares

Comments

Roadzen

Interés en corto

Roadzen (NASDAQ:RDZN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL